|View printer-friendly version|
Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
“Cidara has made notable clinical progress in the second quarter and subsequently as we dosed the first patients in our STRIVE and RADIANT Phase 2 trials of CD101. Both CD101 IV and CD101 Topical have received QIDP and Fast Track designations from the FDA,” said
Second Quarter 2016 Financial Results
- Cash, cash equivalents and short-term investments totaled
$87.1 millionas of June 30, 2016. At December 31, 2015, cash, cash equivalents and short-term investments totaled $107.5 million.
- Research and development expenses were
$8.5 millionand $15.7 millionfor the three and six months ended June 30, 2016, respectively, compared to $4.2 millionand $9.1 millionfor the same periods in 2015. The increases were primarily attributable to clinical development activities for our two product candidates, CD101 IV and CD101 topical, as well as preclinical development activities for our Cloudbreak platform.
- General and administrative expenses were
$3.4 millionand $6.1 millionfor the three and six months ended June 30, 2016, respectively, compared to $2.2 millionand $4.0 millionfor the same periods in 2015. The increase resulted primarily from personnel-related costs to support the growth of our operating activities in addition to costs to operate as a public company.
- Net loss for the three months ended
June 30, 2016was $11.8 million, compared to a net loss of $6.4 millionfor the second quarter of 2015. For the six months ended June 30, 2016and 2015, the company’s net loss was $21.5 millionand $13.2 million, respectively.
- As of
July 31, 2016, Cidara had 13,906,654 common shares outstanding.
Second Quarter 2016 and Subsequent Highlights
- Dosed First Patient in Phase 2 Trial of CD101 IV in Candidemia: Cidara initiated its Phase 2 clinical trial of CD101 IV in candidemia, the STRIVE study, a double-blind study comparing the safety and efficacy of CD101 IV to standard-of-care therapy, caspofungin with an optional step-down to oral fluconazole.
- Dosed First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis: Cidara initiated a Phase 2 clinical trial comparing the safety and efficacy of CD101 topical to standard-of-care oral fluconazole for the treatment of acute vulvovaginal candidiasis (VVC), the RADIANT study. RADIANT is evaluating two topical formulations of CD101: CD101 Ointment and CD101 Gel.
- CD101 Topical Granted QIDP and Fast Track Designations for VVC and Recurrent VVC:
The U.S. Food and Drug Administration( FDA) designated CD101 topical as a Qualified Infectious Disease Product (QIDP), with Fast Track status for its development program, for the treatment and prevention of VVC. The QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), offers certain incentives for the development of new antifungal and antibacterial drugs, including Fast Track, priority review and, if CD101 topical is ultimately approved by the FDA, eligibility for an additional five years of marketing exclusivity under the Hatch-Waxman Act.
- Presented Antifungal Drug Development Program Data at ECCMID 2016: Cidara presented preclinical and clinical data from studies of CD101 at the
European Congress of Clinical Microbiology and Infectious Diseases(ECCMID), including results from the Phase 1 dose-escalation study.
- Presented Data on CD101 at ASM Microbe 2016: At the
American Society for Microbiology (ASM) Microbe2016 meeting in Boston, Cidara made four oral and two poster presentations regarding CD101.
Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial product portfolio comprises two formulations of the company's novel echinocandin, CD101. CD101 IV is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical is being developed for the treatment and prevention of vulvovaginal candidiasis (VVC), a prevalent mucosal infection. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing and other attributes of CD101 IV and CD101 topical, and their potential to treat infections, as well as the intended design of current and future Cloudbreak compounds. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in
|Cidara Therapeutics, Inc.|
|Condensed Consolidated Balance Sheets|
|Cash, cash equivalents, and short-term investments||$||87,089||$||107,514|
|Other current assets||1,142||704|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Total liabilities and stockholders' equity||$||90,024||$||109,974|
|Cidara Therapeutics, Inc.|
|Condensed Consolidated Statements of Operations|
|Three months ended
|Six months ended
|Research and development||$||8,471||$||4,210||$||15,660||$||9,145|
|General and administrative||3,391||2,236||6,087||4,033|
|Total operating expenses||11,862||6,446||21,747||13,178|
|Loss from operations||(11,862||)||(6,446||)||(21,747||)||(13,178||)|
|Other income (expense):|
|Interest income (expense), net||107||32||203||27|
|Total other income (expense)||107||32||203||27|
|Net loss per share, basic and diluted||$||(0.85||)||$||(0.59||)||$||(1.56||)||$||(2.16||)|
|Weighted average shares outstanding used to compute net loss per share, basic and diluted||13,871,938||10,957,150||13,839,864||6,075,134|
Robert H. Uhl Westwicke Partners, LLCManaging Director (858) 356-5932 firstname.lastname@example.org MEDIA CONTACT: Mike Beyer Sam Brown Inc.(312) 961-2502 email@example.com